Previous close | 0.6730 |
Open | 0.6848 |
Bid | 0.6526 x 100 |
Ask | 0.7286 x 100 |
Day's range | 0.6614 - 0.7042 |
52-week range | 0.5000 - 6.8500 |
Volume | |
Avg. volume | 438,309 |
Market cap | 3.132M |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.2000 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.00 |
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting n
Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological postersMARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical candidate, PH-762, an INTASYL compound. The data will be presented i
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound. Preclinical studies demonstrate that PH-762 is effective in silencing PD-1, boosting immune response, and inhibiting t